A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases
- NCT ID
- NCT07782450
- Registry status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- Pfizer
- Conditions
- Idiopathic Inflammatory Myositis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis
Overview
ClinicalTrials.gov lists this study as Not yet recruiting.
Official title: A PHASE 1/2, MULTI-CENTER, OPEN-LABEL, SINGLE- AND MULTIPLE-DOSEESCALATION, DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PRELIMINARY EFFICACY OF PF-08154225, IN PARTICIPANTS WITH AUTOIMMUNE DISEASES INCLUDING ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), OR RHEUMATOID ARTHRITIS (RA), OR IDIOPATHIC INFLAMMATORY MYOSITIS (IIM) OR SYSTEMIC SCLEROSIS (SSC)
Enrollment: 54 participants (Estimated).
What is being studied
No interventions are listed in the registry data.
Who may be eligible
- Ages
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers accepted
- No
ClinicalTrials.gov lists the following eligibility criteria.
Study locations
No study locations are listed in the registry data.
Study details
- Start date
- November 19, 2026
- Primary completion date
- February 22, 2031
- Completion date
- February 22, 2031
- First posted
- August 24, 2026
Source and update information
- Source
- ClinicalTrials.gov
- NCT ID
- NCT07782450
- Registry last updated
- October 1, 2026
- QualifiedStudies registry data refreshed
- October 5, 2026
- QualifiedStudies record fetched
- October 5, 2026
View NCT07782450 on ClinicalTrials.gov
Trial information can change. Confirm current study details with the study team or the registry.
About joining clinical research
Find clinical trials you may match with
QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.
Find clinical trials you may match with | Arthritis studies | Clinical trial FAQ